Metformin and Aging: Could It Slow Age-Related Decline? | Aging
Thumbnail from YouTube. Playing loads the YouTube player.
History & recommendationsOff
Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.
Open saved items & history →About this video
Creator description · original textText language: English
Aging #Published this #Trending review on August 10, 2026, in Volume 18, titled “Metformin at the convergence of aging and longevity" by Jarra Manneh, May Alasmar and Nady El Hajj from the College of Health and Life Sciences, Hamad Bin Khalifa University, Qatar Foundation, Education City 34110, Doha, Qatar; College of Science and Engineering, Hamad Bin Khalifa University, Qatar Foundation, Education City 34110, Doha, Qatar.
#Aging #Metformin #Longevity #Review #Research #OpenAccess #PeerReviewed #Journal #Publishing
DOI - https://doi.org/10.18632/aging.206407
Corresponding author - Nady El Hajj - nelhajj@hbku.edu.qa
Abstract
Metformin is a biguanide and first line drug for type 2 diabetes (T2D) mellitus that is being recognized as a geroprotective agent capable of influencing important hallmarks of aging. Apart from its primary role in lowering blood glucose levels, metformin has been shown to have several effects at the molecular level. It acts by activating the AMPK, which leads to a cascade of downstream events such as the inhibition of mTOR, increased mitochondrial biogenesis, and autophagy, as well as epigenetic modifications. Current findings also showed its capacity to alter the gut microbiota by increasing short-chain fatty acid producing bacteria, indicating the involvement of other systemic pathways that aid in lowering inflammation, increasing metabolic fitness, and keeping epigenetic stability. The Targeting Ageing with Metformin (TAME), a landmark trial which seeks to evaluate metformin’s ability to slow down several age-associated diseases, could lead to a paradigm shift in the clinical approach to aging. This article looks at metformin’s various effects on aging and longevity by consolidating findings from cellular, molecular, and organismal levels. It also calls for more studies and trials on metformin and aging.
Sign up for free Altmetric alerts about this article -
https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206407
Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts
Keywords - aging, metformin, AMPK, mTOR, epigenetic modifications
To learn more about the journal, please visit https://www.Aging-US.com and connect with us on social media at:
Bluesky - https://bsky.app/profile/aging-us.bsky.social
ResearchGate - https://www.researchgate.net/journal/Aging-1945-4589
X - https://twitter.com/AgingJrnl
Facebook - https://www.facebook.com/AgingUS/
Instagram - https://www.instagram.com/agingjrnl/
LinkedIn - https://www.linkedin.com/company/aging/
Reddit - https://www.reddit.com/user/AgingUS/
Pinterest - https://www.pinterest.com/AgingUS/
YouTube - https://www.youtube.com/@Aging-US
Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc
MEDIA@IMPACTJOURNALS.COM
Aging Journal · 2 min · Source published: 2026-08-26
Added to Harbor: 10/23/2026
Original on YouTube ↗Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.